OneOme®

PGx Informed Health Benefits for Employers

Co-founded by Mayo Clinic, OneOme is a full-service PGx partner that helps organizations unlock the power of precision medicine.

Pharmacogenomics (PGx) is the study of how genes affect the way a person responds to medications. Pharmacogenomic testing may help optimize prescribing, reduce trial and error, and reduce costs for employers and employees alike.

RightMed®

RightMed® for Populations

COMPREHENSIVE PGx TEST

The RightMed test covers 27 genes that may impact how a patient responds to certain medications used to treat varied medical conditions.

EVIDENCE-BASED

The RightMed test's gene coverage has been selectively curated by a group of pharmacists, physicians, and scientists using OneOme's rigorous standards for pharmacogenomic evidence. Each sample is analyzed at OneOme's CLIA-certified, CAP-accredited in-house laboratory.



IDENTIFICATION

90% of the general population may have a gene variant that may affect observed medication variability.[1]

IMPACT

The 2023 PREPARE Study, which included over 6,000 patients, showed that adverse drug reactions were reduced by around 30% when certain prescriptions were informed by PGx test results.[2]

IMPLEMENTATION

OneOme's team works with employer groups to create customized PGx programs for employee/patient safety and personalized precision medicine results.

PGX MAY BE BENEFICIAL IN GENE DRUG INTERACTIONS FOR MEDICATIONS PRESCRIBED FOR:

- Mental Health
  Depression
  Anxiety
- Oncology
  Chemotoxicity
  Pediatric Cancer
- Pain Management
  Surgical Pharm
- Cardiology
  Geriatric Medicine
  Polypharmacy

1.Van Driest SL, et al. Clin Pharmacol Ther. 2014;95(4):423-431.
2.Swen, J, et al. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, clusterrandomised crossover implementation study. The Lancet. 2023. https://doi.org/10.1016/S0140-6736(22)01841-4